Impact of the excision repair cross-complementation group 1 predictive biomarker on toxicity and quality of life in advanced non-small cell lung cancer patients randomized in a large, multicenter, cisplatin-based phase III trial

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt